Overview

A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD

Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the tolerability and effectiveness of atomoxetine in the treatment of attention problems, hyperactivity, and impulsivity in children with ASD, and secondarily, to evaluate the possible response to atomoxetine on the core symptoms of ASD
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Atomoxetine Hydrochloride